Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer

• DOI: 10.1097/01.ogx.0001050544.16643.94
• Publication Date: 2024-08-15T17:01:22Z
• Authors: Kathy Han; Jinfeng Zou; Zhen Zhao; Zeynep Baskurt; Yangqiao Zheng; Elizabeth Barnes; Jennifer Croke; Sarah E. Ferguson; Anthony Fyles; Lilian Gien; Adam Gladwish; Magali Lecavalier...; Stephanie Lheureux; Jelena Lukovic; Helen Mackay; Eve-Lyne Marchand; Ur Metser; Michael Milosevic; Amandeep S. Taggar; Scott V. Bratman; Eric Leung
• Keywords: Minimal Residual Disease; Circulating tumor DNA

(Abstracted from J Clin Oncol 2023;42:431–440 The majority of cervical cancers are caused by human papillomavirus (HPV), and despite treatment with chemoradiation (CRT), up to 40% patients locally advanced cancer will relapse. Current prognostic factors poor predictors relapse; however, detection HPV circulating tumor DNA (ctDNA) after CRT may identify those at higher risk